Pancreatic Cancer

Byetta Class Action News – 5/2/2012: Did you take Byetta? Please contact us today if you took Byetta and later experienced harmful side effects. We will connect you with a lawyer that is experienced in complex litigation that may be able to help you recover monetary damages.

Byetta Class Action: Tumor cells usually resort to a more expedient way of eliminating the second copy of a tumor suppressor gene. Their strategy depends on the fact that the two partners in a human chromosome pair (such as the two thirteenth chro­mosomes, each of which carries an Rb gene copy) often line up next to one another in parallel array, look each other over, compare their respective DNA sequences, and then swap ge­netic information. One frequent result is that a gene sequence present on one chromosome will now replace the corresponding sequence carried by its partner. Before this information transfer, two distinct versions of a gene may have resided on the two paired chromosomes; afterward, one of these versions is lost, being replaced by a duplicated version of the gene originally present on the other chromosome.

Precancerous tumor cells on their way to becoming actively malignant will often use this trick to eliminate both copies of a tumor suppressor gene that has been holding back their growth. They will first mutate to inactivity one copy of the gene and then eliminate its partner through this loss-of-heterozygosity homogenization. Importantly, the chromosomal swaps that generate this homogenization often involve large regions of the chromosome surrounding the tu­mor suppressor gene, not just the gene itself. Hundreds of genes residing to the left and the right of the tumor suppres­sor gene on a chromosome will also become homogenized. Of course, the homogenization of neighboring gene copies is irrelevant for the growth of the developing tumor cells. These neighboring genes are nothing more than innocent by­standers. It is realty only the tumor suppressor gene that the tumor cell is intent on eliminating through use of the homog­enization trick.

Two things changed in modern times. We now live much longer than we used to. By the middle of the twentieth century, many of us began to live for seventy or eighty years, an age when this disease strikes frequently. A hundred years earlier, relatively few survived long enough to confront it. Our diet also changed from one heavy in grains and vegetables to fare that increasingly emphasized meat and large amounts of fat. The effects of diet are apparent from epidemiology: There are regions of Africa whose inhabitants follow a diet based al­most exclusively on vegetables and grains. These people run a risk of colon cancer that is less than one-tenth of that seen in the West.

Byetta Class Action News: More information about your search

Byetta Class Action: Some humans make these detoxifying enzymes at high levels, while others produce them at much lower levels. These differences, which are heritable, offer us the opportu­nity to understand the roles of these enzymes in protecting cells against attack by various carcinogens. For example, do individuals with low levels of these protective enzymes con­tract cancer more often than those having high levels? In fact, some striking differences have been uncovered. Smokers who make low levels of the NAT enzyme (N-acetyl transferase) run as much as two and a half times the risk of bladder cancer compared to smokers having high levels of the NAT enzyme. Low levels of a second detoxifying en­zyme, GSTMl (glutathione-S-transferase Ml), result in a threefold increase in the risk of lung cancer. These findings suggest that we may one day be able to calculate smokers’ risk of cancer based on their lifelong cigarette consumption and their levels of detoxifying enzymes.

Some mutagens succeed in penetrating this complex array of protective devices. Having escaped inactivation, these mutagens may proceed to react with and thereby damage the DNA molecules carried in the cell’s chromosomes. Every human cell sustains thousands of such mutagenic attacks every day. But in spite of this barrage, the cell’s DNA emerges at the end of the day relatively unscathed. This discrepancy demands explanation.

Close scrutiny of the machinery used by the cell to copy its DNA molecules reveals a similar discrepancy. The process by which cells replicate DNA in preparation for cell division is prone to error. Immediately after DNA poly­merase—the enzyme responsible for DNA replication—has copied a stretch of DNA, as many as one in every thousand bases of the newly made DNA strand may be incorrect, hav­ing been mistakenly inserted by the polymerase. But as be­fore, the actual rate at which mutations accumulate in the DNA is much lower. Somehow, the vast majority of these initial copying mistakes are not perpetuated in the DNA.

This dynamic has direct consequences for tumor forma­tion: If the DNA repair process fails, large numbers of altered bases will accumulate in a cell’s DNA. This means that the rate at which mutations accumulate is influenced by at least three distinct processes: damage inflicted on the DNA by mutagens of foreign or internal origin, mistakes made during DNA copying, and defects in die DNA repair machinery responsible for erasing the damage created by mutagens or miscopying. Since mutation is the engine that drives tumor progression, all three of these processes are likely to be involved in one way or another in causing cancer.

Byetta Class Action News: Additional Information and Resources

Byetta Class Action: Knowing about mutant genes allows us to trace the roots of cancer back to discrete, identifiable changes in the central controlling molecule of the cell, its DNA. But in one sense, these genetic discoveries are sterile and uninformative. Genes are pure information, nothing more than mathemati­cal abstractions. Studied in isolation, they tell us little about the real life of the cell. Moreover, the sequence of DNA bases that constitutes a gene usually reveals little about how this gene operates. So, even after we know that one or another gene is mutated during the development of a cancer, we still understand next to nothing about the mechanisms by which this mutant gene causes abnormal cell growth. Fortunately, molecular biology provides us with a useful train of logic that leads us toward an understanding of gene function. Genes instruct the cells around them to make specific pro­teins. It is the proteins that do the work of the genes. Proteins catalyze biochemical reactions or create elaborate physical structures. To understand how a gene works, we must know intimately how its protein functions.

In one sense, the roles played by the normal versions of oncoproteins are obvious: They help the normal cell regulate its growth. Unfortunately, this statement does not take us very far; it only restates the problem, and in a way that is not terribly useful. A more productive tack is suggested by the following question: Precisely how do normal cells know when to grow and when to hold back from growth? At any moment, the great majority of cells in our body are in a quiescent state. Only in tissues that renew themselves constantly, such as the colonic epithelium, the bone marrow (which generates new blood cells), and the skin, does one find large numbers of cells actively growing and dividing.

These dramatic differences in the proliferation rates of tissues bring us back to our question: Precisely how do any of these cells know when they should grow? The issue becomes even more complicated in the case of embryonic development, where cell proliferation results in the creation of new, complex tissues rather than the maintenance of an existing tissue architecture.

Our use of the term or terms Byetta Class Action is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Byetta Class Action News visit our site often.

The post Byetta Class Action Top News appeared first on Seedol.com.

Byetta Class Action: Tumor cells usually resort to a more expedient way of eliminating the second copy of a tumor suppressor gene. Their strategy depends on the fact that the two partners in a human chromosome pair (such as the two thirteenth chro­mosomes, each of which carries an Rb gene copy) often line up next to one another in parallel array, look each other over, compare their respective DNA sequences, and then swap ge­netic information. One frequent result is that a gene sequence present on one chromosome will now replace the corresponding sequence carried by its partner. Before this information transfer, two distinct versions of a gene may have resided on the two paired chromosomes; afterward, one of these versions is lost, being replaced by a duplicated version of the gene originally present on the other chromosome.

Precancerous tumor cells on their way to becoming actively malignant will often use this trick to eliminate both copies of a tumor suppressor gene that has been holding back their growth. They will first mutate to inactivity one copy of the gene and then eliminate its partner through this loss-of-heterozygosity homogenization. Importantly, the chromosomal swaps that generate this homogenization often involve large regions of the chromosome surrounding the tu­mor suppressor gene, not just the gene itself. Hundreds of genes residing to the left and the right of the tumor suppres­sor gene on a chromosome will also become homogenized. Of course, the homogenization of neighboring gene copies is irrelevant for the growth of the developing tumor cells. These neighboring genes are nothing more than innocent by­standers. It is realty only the tumor suppressor gene that the tumor cell is intent on eliminating through use of the homog­enization trick.

Two things changed in modern times. We now live much longer than we used to. By the middle of the twentieth century, many of us began to live for seventy or eighty years, an age when this disease strikes frequently. A hundred years earlier, relatively few survived long enough to confront it. Our diet also changed from one heavy in grains and vegetables to fare that increasingly emphasized meat and large amounts of fat. The effects of diet are apparent from epidemiology: There are regions of Africa whose inhabitants follow a diet based al­most exclusively on vegetables and grains. These people run a risk of colon cancer that is less than one-tenth of that seen in the West.

Byetta Class Action News: More information about your search

Byetta Class Action: Some humans make these detoxifying enzymes at high levels, while others produce them at much lower levels. These differences, which are heritable, offer us the opportu­nity to understand the roles of these enzymes in protecting cells against attack by various carcinogens. For example, do individuals with low levels of these protective enzymes con­tract cancer more often than those having high levels? In fact, some striking differences have been uncovered. Smokers who make low levels of the NAT enzyme (N-acetyl transferase) run as much as two and a half times the risk of bladder cancer compared to smokers having high levels of the NAT enzyme. Low levels of a second detoxifying en­zyme, GSTMl (glutathione-S-transferase Ml), result in a threefold increase in the risk of lung cancer. These findings suggest that we may one day be able to calculate smokers’ risk of cancer based on their lifelong cigarette consumption and their levels of detoxifying enzymes.

Some mutagens succeed in penetrating this complex array of protective devices. Having escaped inactivation, these mutagens may proceed to react with and thereby damage the DNA molecules carried in the cell’s chromosomes. Every human cell sustains thousands of such mutagenic attacks every day. But in spite of this barrage, the cell’s DNA emerges at the end of the day relatively unscathed. This discrepancy demands explanation.

Close scrutiny of the machinery used by the cell to copy its DNA molecules reveals a similar discrepancy. The process by which cells replicate DNA in preparation for cell division is prone to error. Immediately after DNA poly­merase—the enzyme responsible for DNA replication—has copied a stretch of DNA, as many as one in every thousand bases of the newly made DNA strand may be incorrect, hav­ing been mistakenly inserted by the polymerase. But as be­fore, the actual rate at which mutations accumulate in the DNA is much lower. Somehow, the vast majority of these initial copying mistakes are not perpetuated in the DNA.

This dynamic has direct consequences for tumor forma­tion: If the DNA repair process fails, large numbers of altered bases will accumulate in a cell’s DNA. This means that the rate at which mutations accumulate is influenced by at least three distinct processes: damage inflicted on the DNA by mutagens of foreign or internal origin, mistakes made during DNA copying, and defects in die DNA repair machinery responsible for erasing the damage created by mutagens or miscopying. Since mutation is the engine that drives tumor progression, all three of these processes are likely to be involved in one way or another in causing cancer.

Byetta Class Action News: Additional Information and Resources

Byetta Class Action: Knowing about mutant genes allows us to trace the roots of cancer back to discrete, identifiable changes in the central controlling molecule of the cell, its DNA. But in one sense, these genetic discoveries are sterile and uninformative. Genes are pure information, nothing more than mathemati­cal abstractions. Studied in isolation, they tell us little about the real life of the cell. Moreover, the sequence of DNA bases that constitutes a gene usually reveals little about how this gene operates. So, even after we know that one or another gene is mutated during the development of a cancer, we still understand next to nothing about the mechanisms by which this mutant gene causes abnormal cell growth. Fortunately, molecular biology provides us with a useful train of logic that leads us toward an understanding of gene function. Genes instruct the cells around them to make specific pro­teins. It is the proteins that do the work of the genes. Proteins catalyze biochemical reactions or create elaborate physical structures. To understand how a gene works, we must know intimately how its protein functions.

In one sense, the roles played by the normal versions of oncoproteins are obvious: They help the normal cell regulate its growth. Unfortunately, this statement does not take us very far; it only restates the problem, and in a way that is not terribly useful. A more productive tack is suggested by the following question: Precisely how do normal cells know when to grow and when to hold back from growth? At any moment, the great majority of cells in our body are in a quiescent state. Only in tissues that renew themselves constantly, such as the colonic epithelium, the bone marrow (which generates new blood cells), and the skin, does one find large numbers of cells actively growing and dividing.

These dramatic differences in the proliferation rates of tissues bring us back to our question: Precisely how do any of these cells know when they should grow? The issue becomes even more complicated in the case of embryonic development, where cell proliferation results in the creation of new, complex tissues rather than the maintenance of an existing tissue architecture.

Our use of the term or terms Byetta Class Action is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Byetta Class Action News visit our site often.

The post Byetta Class Action appeared first on Seedol.com.